CorMedix (CRMD) Proxy filing summary

Executive summary

• Achieved $311.7 million in total revenue for 2025, with $258.8 million from DefenCath and $52.9 million from the Melinta portfolio after its acquisition in August 2025.

• Net income for 2025 was $163.0 million, or $2.04 per diluted share, reversing a net loss of $17.9 million in 2024.

• The Melinta acquisition expanded the product portfolio and commercial footprint, positioning for long-term growth.

• 2026 is expected to be a transitional year due to changes in DefenCath reimbursement, emphasizing operational execution and financial flexibility.

Voting matters and shareholder proposals

• Election of seven directors for one-year terms.

• Advisory vote on executive compensation (Say-on-Pay) for 2025.

• Ratification of CBIZ CPAs P.C. as independent auditor for 2026.

• Ratification of historical amendments to Series E and Series C-3 Preferred Stock certificates of designation (COD Amendments Proposal).

• Amendments to the Charter for technical updates and streamlining.

• Class Voting Proposal to clarify that only affected preferred stockholders vote on amendments solely impacting preferred stock.

• Exclusive Forum Proposal to designate Delaware courts as the exclusive forum for certain legal actions.

• Proposal to limit certain officers' personal liability as permitted by Delaware law.

• Adjournment Proposal to allow further solicitation if necessary for key proposals.

Board of directors and corporate governance

• Board consists of seven members, with a combined Chair/CEO role and a Lead Independent Director for oversight.

• All directors except the CEO are independent; committees include Audit, Compensation, Nominating and Governance, and Strategy.

• Board and committees meet regularly, with all directors attending at least 75% of meetings.

• Stock ownership guidelines and clawback policies are in place for directors and executives.